Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
Very low or no dividends
Very poor margins and returns
Risk / Profitability
Risk: High
Profitability: Favourable
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
Very low or no dividends
Very poor margins and returns
$ 0.43
About
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's...
About
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops...
